Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CMVLF)
OTHER OTC:CMVLF
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
0.08Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting strategic collaboration, financial stability, and progress in clinical programs. However, challenges in ongoing arbitration and regulatory uncertainties were noted, but they did not overshadow the advancements and strategic gains made by the company.Company Guidance
During the Cellectis Full Year 2024 Earnings Conference Call, the company provided guidance on various metrics, highlighting significant progress and future plans. Cellectis announced the commencement of three programs under their collaboration with AstraZeneca, including allogeneic CAR T programs for hematological malignancies and solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca's additional equity investment of $140 million resulted in them owning approximately 44% of Cellectis' share capital. Cellectis expects to present Phase 1 data for their UCART22 product in Q3 2025, with regulatory discussions planned to align on a Phase 2 strategy. The NATHALI-01 study for UCART20x22 in non-Hodgkin lymphoma continues, with Phase 1 data expected in late 2025. The company's cash position was strengthened, enabling a cash runway until mid-2027, with cash, cash equivalents, and fixed term deposits totaling $264 million as of December 31, 2024. Cellectis emphasized its focus on advancing clinical trials, leveraging its technology, and expanding strategic partnerships to address unmet medical needs.Strategic Collaboration with AstraZeneca
Cellectis announced the start of R&D activities for three programs under their collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy. AstraZeneca completed an additional equity investment of $140 million, owning approximately 44% of Cellectis' share capital.
Financial Strength and Cash Runway
Cellectis' cash, cash equivalents, restricted cash, and fixed term deposits amounted to $264 million as of December 31, 2024, up from $156 million in 2023. The company is confident that their cash runway will fund operations into mid-2027.
UCART22 and UCART20x22 Progress
Cellectis received Orphan Drug Designation and Rare Pediatric Disease designation for UCART22. The company expects to present Phase 1 data for UCART22 in the third quarter of 2025 and for UCART20x22 in late 2025.
Manufacturing and Innovation
Cellectis showcased promising CAR T strategies targeting solid tumors using TALEN gene editing technology, presenting preclinical data at major conferences and publishing articles in scientific journals.
---
CMVLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CMVLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $1.25 | $1.25 | 0.00% |
| Nov 04, 2024 | $1.99 | $1.99 | 0.00% |
| Aug 06, 2024 | $2.00 | $2.10 | +5.00% |
| May 28, 2024 | $2.68 | $2.61 | -2.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cellectis SA (CMVLF) report earnings?
Cellectis SA (CMVLF) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cellectis SA (CMVLF) earnings time?
Cellectis SA (CMVLF) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMVLF EPS forecast?
CMVLF EPS forecast for the fiscal quarter 2025 (Q1) is -0.15.
---